Efficacy and Safety Study of SUNPG1623
- Conditions
- Active Psoriatic Arthritis
- Interventions
- Drug: PLACEBODrug: SUNPG1623 IIIDrug: SUNPG1623 IIDrug: SUNPG1623 IDrug: SUNPG1623 IV
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 391
- Registration Number
- NCT02980692
- Locations
- 🇺🇸
SPARC Site 1, Middleburg Heights, Ohio, United States
Efficacy and Safety Study of SUNPG1622
- Conditions
- Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
- Interventions
- Drug: Placebo doseDrug: SUNPG1622 I dose
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 180
- Registration Number
- NCT02980705
- Locations
- 🇵🇱
SPARC site 3, Elbląg, Poland
🇺🇸SPARC Site 1, Middleburg Heights, Ohio, United States
🇪🇸SPARC site 2, A Coruña, Spain
One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™
- Conditions
- Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 20
- Registration Number
- NCT02962284
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Drug: OTX-101 0.09%
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 258
- Registration Number
- NCT02845674
A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: Zytiga® (Abiraterone Acetate)Drug: SoluMatrix™ (Abiraterone Acetate)
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 53
- Registration Number
- NCT02737332
- Locations
- 🇺🇸
North Idaho Urology, Coeur d'Alene, Idaho, United States
🇺🇸Chesapeake Urology Research Associates, Towson, Maryland, United States
🇺🇸Lincoln Urology, PC, Lincoln, Nebraska, United States
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Drug: vehicle of OTX-101Drug: cyclosporine
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 745
- Registration Number
- NCT02688556
- Locations
- 🇺🇸
Martel Eye Medical Group, Rancho Cordova, California, United States
🇺🇸Fifth Avenue Eye Associates, New York, New York, United States
🇺🇸Cincinnati Eye Institute, Edgewood, Kentucky, United States
To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis
- Conditions
- Active Rheumatoid Arthritis
- Interventions
- Drug: Treatment IDrug: Treatment IIDrug: Treatment III
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 150
- Registration Number
- NCT02534896
- Locations
- 🇧🇪
Sun Pharma Site 23, Brussels, Belgium
🇧🇪Sun Pharma Site 20, Merksem, Belgium
🇧🇪Sun Pharma Site 16, Leuven, Belgium
ABSORICA in Patients With Severe Recalcitrant Nodular Acne
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 201
- Registration Number
- NCT02457520
- Locations
- 🇺🇸
Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
- Conditions
- Keratoconjunctivitis SiccaDry Eye Disease
- Interventions
- Drug: OTX-101 0.05%Drug: OTX-101 0.09%Drug: Vehicle
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 455
- Registration Number
- NCT02254265
Bio-equivalence Study Between SAPHRIS and Asenapine
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 65
- Registration Number
- NCT01948024
- Locations
- 🇺🇸
Woodland International Research Group, Inc., Little Rock, Arkansas, United States
🇺🇸Collaborative Neuroscience Network, LLC, Garden Grove, California, United States
🇺🇸Clinical Innovations, Inc, Costa Mesa, California, United States